MOMENTUM: Pemvidutide Boasts "Class-Leading" Lean Mass Preservation with Weight Loss

Published Date: 27 Jun 2024

MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

2.

EVP Beats Cisplatin for Resectable MIBC

3.

For elderly, unfit patients, the all-oral AML regimen shows promise.

4.

Study sets benchmark for treatment of advanced cervical cancer

5.

For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot